frontline endocrine therapies and ribociclib in early stage hr her2- breast cancer
Published 1 year ago • 176 plays • Length 1:39Download video MP4
Download video MP3
Similar videos
-
1:41
adapt trial: endocrine ribociclib vs. chemotherapy in hr /her2- early breast cancer
-
2:00
ribociclib in early breast cancer | nejm
-
1:12
remaining questions on the use of frontline cdk4/6 inhibitors endocrine therapy
-
2:11
the use of frontline cdk4/6 inhibitors endocrine therapy in metastatic breast cancer
-
3:08
adding ribociclib to endocrine therapy shows an improvement in invasive dfs in hr /her2 bc patients
-
0:36
maintenance w/ et ribociclib after 1l chemotherapy in hr /her2- metastatic breast cancer
-
2:23
natalee: ribociclib nsai as adjuvant treatment in patients with hr /her2− early breast cancer
-
1:51
natalee: ribociclib and nsai in hr /her2- early breast cancer
-
1:48
natalee and monarche: ribociclib and abemaciclib in hr /her2- breast cancer
-
1:11
unmet needs in the use of cdk4/6 inhibitors in early-stage hr /her2- breast cancer
-
2:13
dr. tripathy on frontline endocrine therapies in hr breast cancer
-
3:44
alternate: neoadjuvant endocrine treatment in er /her2- breast cancer
-
1:43
composite biomarkers predictive of palbociclib endocrine treatment benefit in early breast cancer
-
2:46
right choice: ribociclib et vs combo chemo in aggressive hr /her2− advanced breast cancer
-
1:26
ribecca: ribociclib, a cdk4/6 inhibitor in er breast cancer
-
1:19
monaleesa-2: improved os seen in hr advanced breast cancer treated with ribociclib letrozole
-
10:34
frontline therapy in hr-positive breast cancer
-
4:03
monarche 4-year: abemaciclib endocrine therapy for hr , her2-, node-positive, high-risk early bc
-
1:25
current state of cdk4/6 inhibitors in metastatic her2-negative breast cancer